-
Son Suk-ku and Eita Nagayama Star in Netflix’s 'The Blue Road' Cross-Border Crime Thriller
-
DiDi Advances Robotaxi Operations in China with New R2 Vehicle and Expanded Safety Infrastructure
-
Moving to a New State? Your Healthcare Might Get More Complicated
-
Smart Car Seats Tested: Do Sensors and Apps Actually Improve Safety?
-
South Africa’s Economic Shift: Why Services Must Lead Job Creation Beyond Manufacturing
-
5 Strategies for Fort Worth Households to Reduce Summer Electricity Costs
-
Lethbridge Council to Vote on $80 Million Capital Improvement Program
-
Central Bank of Malta Links Energy Subsidies to Middle East Conflict and Price Volatility
-
Redmi Note 18 5G Battery Specs Leaked: Larger Capacity in Chinese Variant
-
Shomari Figures Defies Redistricting in Alabama Amid Disaster Relief Crisis
-
COP31 Presidency Publishes First Draft Cover Decision on Climate Action
-
BYD Dolphin G Leasing Deal: Plug-in Hybrid Supermini Available from £174 a Month
-
EU Club Group Files Antitrust Complaint Against UEFA Over Prize Money
-
Egypt Opens Registration for 2027 Total Solar Eclipse Viewing Packages
-
Heat and El Niño Drive Surge in Preterm Births Across Southern Africa
-
French Economy Shrinks 0.1% as Consumer Confidence Slumps
-
China's Factory Activity Contracts as Export Orders Weaken
-
Wall Street Ends Turbulent Week Higher Despite Inflation and AI Jitters
-
US Retail Sales and Fed Minutes Set Up a Critical Test for Consumers
-
Kansas City Fed Chief Says Inflation Is Still Running Too Hot
-
Oil Heads for Second Weekly Loss as Supply Surplus Emerges
-
Asian Markets Slide as AI Concerns Hit Chip Stocks
-
Brazil Faces Debt and Inflation Test as Lula Prepares Fourth Term
-
Tom Brady’s Viral Reaction to Deebo Samuel’s Trick-Play Touchdown
-
Canada Signals Openness to Chinese Automakers if US Trade Talks Fail
-
Canada Expands Asian Trade Push as US Negotiations Resume
-
US Mortgage Rate Falls for Fourth Week but Remains Above 7%
-
US Jobless Claims Rise to 200,000 but Layoffs Remain Historically Low
-
13 Native American-Owned Restaurants in Arizona to Experience Indigenous Culinary Traditions
-
Italy Raises 2026 Growth View but Warns Energy Will Keep Inflation High
-
Best Digital Photo Frames 2026: Aura, Skylight, and Amazon Compared
-
Euro-Area Growth Slows to 0.4% While Employment Stalls
-
UK Economy Grows 0.7% in Third Quarter as Services Lead Expansion
-
US Wholesale Inflation Eases Monthly but Hits a Four-Year Annual High
GSK spin-off to create consumer healthcare giant
British drugs giant GlaxoSmithKline on Monday demerges its newly-named consumer healthcare unit Haleon, resulting in what is set to be London's largest new stock market listing in more than a decade.
The new company -- owning brands including Sensodyne toothpaste, pain relief drug Panadol and cold treatment Theraflu -- is set for a valuation of about £40 billion ($47.4 billion) when it begins trading on the London stock market, according to Bloomberg.
The major strategy shift by GSK chief executive Emma Walmsley comes after she has faced intense activist shareholder pressure over the company's delays in producing Covid jabs and treatments.
- 'Landmark London listing -
"This will be the largest London stock market listing in a decade, with the new company becoming a big beast with a new skin in the consumer goods world," said Susannah Streeter, senior investment and markets analyst at Hargreaves Lansdown.
It is set to be the capital's biggest listing since Swiss mining giant Glencore was valued at £38 billion on entry in 2011.
GSK, which owns 68 percent of Haleon, plans to retain six percent of the group following the spin-off.
US pharmaceutical titan Pfizer has said it plans to sell its 32-percent minority stake.
Walmsley, who had led the consumer unit prior to her promotion as head of GSK in 2017, has described the demerger as the group's most significant corporate change in 20 years.
The split sees GSK "parcelling off a considerable quantity of its sizeable debt pile into Haleon, expected to be around £10 billion", Streeter said.
Haleon could join London's top-tier FTSE 100 depending on its market valuation.
Walmsley, part of a group of less than 10 women chief executives running companies on the benchmark index, sees more long-term value in the demerger than a sale.
GSK at the start of the year rejected a £50 billion bid for the unit from consumer goods titan Unilever.
- Vaccine push -
Alongside the demerger, GSK is expanding further into the field of vaccines, having in May snapped up US biopharmaceutical firm Affinivax for up to $3.3 billion.
Also this year, the British company spent $1.9 billion on US group Sierra Oncology, a specialist in medicines for rare forms of cancer.
Keith Bowman, analyst at Interactive Investor, said the demerger was aimed at giving GSK "increased management focus to each respective business".
This was the case "particularly for its pharma business which has underperformed rivals such as (Covid vaccine-maker) AstraZeneca over recent years", he told AFP.
GSK is set to receive £7 billion in dividends at separation.
The consumer healthcare division, whose portfolio of products includes also Centrum multivitamins and anti-inflammatory Voltaren, generates annual sales of about £10 billion.
Haleon will be headquartered in Weybridge, southwest of London.
"The idea is that a more focused consumer business will help boost sales," said Streeter.
"There will be no change at the top... which is a vote of confidence in Brian McNamara, a former Procter & Gamble executive who has led the division for eight years."
J.Fankhauser--BTB